

## GLP-1 Pipeline Update: November 2024

Prime Therapeutics actively monitors the GLP-1 landscape and provides a snapshot of what is on the horizon. The table below displays the earliest potential approval timeline for the agents listed. Time periods are based on available information or are estimated using phase 3 trial completion dates.

Drug/dosage form	T2DM	Obesity or overweight	T2DM + CVD	Obesity or overweight + CVD	Diabetic nephropathy + T2DM + CKD	Diabetic retinopathy + T2DM	T2DM + PAD	OSA + obesity	OA of knee + obesity	Chronic HF + obesity	MASH	Alzheimer's disease
exenatide (Byetta, Bydureon Bcise)/SC	FDA-approved											
dulaglutide (Trulicity)/SC	FDA-approved		FDA-approved									
liraglutide (Victoza)/SC	FDA-approved		FDA-approved									
liraglutide (Saxenda)/SC		FDA-approved										
liraglutide/insulin degludec (Xultophy)/SC	FDA-approved											
lixisenatide/insulin glargine (Soliqua)/SC	FDA-approved											
semaglutide (Ozempic)/SC	FDA-approved		FDA-approved		FDA decision Jan-25	2027	2026					2026
semaglutide (Rybelsus)/oral	FDA-approved		2026									2027
semaglutide (Wegovy)/SC		FDA-approved		FDA-approved					2026	2025		
tirzepatide (Mounjaro)/SC	FDA-approved											
tirzepatide (Zepbound)/SC		FDA-approved						FDA decision Dec-24		4Q2025		
cagrilintide + semaglutide/SC	2026	4Q2025										
orforglipron/oral	2026	2026						2027				
retatrutide/SC	2027	2027		2027					2027			
semaglutide (NN9931)/SC											2025	

Drug/dosage form	T2DM	Obesity or overweight	T2DM + CVD	Obesity or overweight + CVD	Diabetic nephropathy + T2DM + CKD	Diabetic retinopathy + T2DM	T2DM + PAD	OSA + obesity	OA of knee + obesity	Chronic HF + obesity	MASH	Alzheimer's disease
semaglutide + insulin icodex/SC	2025											
survodutide/SC	4Q2026	2027									2027	

## GLOSSARY

CKD = Chronic kidney disease

CVD = Cardiovascular disease

FDA = Food and Drug Administration

GLP-1 = Glucagon-like peptide-1 receptor agonist

HF = Heart failure

MASH = Metabolic dysfunction-associated steatohepatitis

OA = Osteoarthritis

OSA = Obstructive sleep apnea

PAD = Peripheral arterial disease

SC = Subcutaneous

T2DM = Type 2 diabetes mellitus

## DISCLAIMER

*The drug pipeline is fluid; the dates and information within this publication are subject to change. Nothing herein is or shall be construed as a promise or representation regarding past or future events and Prime Therapeutics expressly disclaims any and all liability relating to the use of or reliance on the information contained in this presentation. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to, or disclosed to others at any time without the prior written consent of Prime Therapeutics.*

*All brand names are property of their respective owners.*